Decentralized Clinical Trials Promised Faster Recruitment. The Evidence on Actual Performance Is In.
Dr. Dereck Mush, MD, MBA
adsilico
University of Leeds spinout whose Virtual Chimera technology tests medical devices across generated virtual patient populations.
What they do
adsilico combines generative AI virtual anatomies with physics-based simulation so device makers can study performance across diverse virtual populations before and alongside human trials. Announced a 10 million pound Series A on October 26, 2026, led by PXN Ventures with Northern Gritstone and Parkwalk participating, following a 3.5 million pound seed in 2024.
The record
- Vertical
- Clinical Trials
- Sub-segment
- In silico trials
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Leeds, United Kingdom
- Region
- Europe
- Founded
- 2022
- Total funding
- $18M raised
Notable investors: PXN Ventures, Northern Gritstone, Parkwalk.
Also in Clinical Trials
Related on The Signal
Dr. Dereck Mush, MD, MBA
The End of Phase-Gated Trials: How ARPA-H's SURPASS Program Reengineers Biomedical R&D
Dr. Dereck Mush, MD, MBA
Pig Kidney Transplants Are Now in Human Trials. Here Is What EXPAND and Its Rivals Actually Have to Prove
Dr. Dereck Mush, MD, MBA
Oracle and AstraZeneca: Bringing Clinical Trials Closer to Care
Dr. Dereck Mush, MD, MBA